In 2014, topiramate became the first medication approved for migraine prevention in adolescents by the Food and Drug Administration. 1 The drug has several proposed mechanisms that include modulatory effects on sodium channels, calcium (L-and T-type) channels, glutamate and g-aminobutyric acid pathways, carbonic anhydrase isoenzymes, and glutamate subtype a-amino-3-hydroxy-5-methylisoxazole-5-proprionic acid/ kainate receptors. [2] [3] [4] Topiramate has been used in the pediatric population to treat epilepsy and episodic and chronic migraines.
Topiramate's age-specific adverse effects are not well known; however, appetite reduction and related weight loss are some of those most commonly reported in both pediatric and adult populations. 5 The specific mode of action behind topiramate's weightmodifying properties is unclear. 4 Although promising data suggest topiramate may inhibit several carbonic anhydrase isoenzymes, a property shared by zonisamide, a medication with similar weight loss properties, [6] [7] [8] the theory currently remains speculative. 4 Multiple studies of topiramate treatment of partial-onset and generalized epilepsy in youth describe rates of weight loss/anorexia ranging from 10% in 1 study 9 to 39% to 40% in 3 independent studies. [10] [11] [12] Although the majority of participants across studies remained on topiramate, several discontinued use due to weight loss/anorexia. 13, 14 Authors agree that weight loss and anorexia are not common enough to preclude topiramate use in children, but the side effects merit concern.
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RESULTS
Seven female adolescents treated with topiramate (ages ranged from 13 to 18 years; mean = 16.43 years) were diagnosed with EDs (Table 1) . Of these patients, 4 were diagnosed with eating disorder not otherwise specified (cases 1, 4, 6, and 7), 2 with anorexia nervosa (cases 2 and 3), and 1 with bulimia nervosa (case 5). All patients had received topiramate for migraine or chronic headache, with dosages ranging from 25 mg twice daily to 150 mg daily. The most common physical comorbidity reported was postural orthostatic tachycardia syndrome (POTS) in 4 patients (cases 2, 4, 5, and 6). The most common psychological comorbidities included major depressive disorder (cases 1, 5, and 6) and various anxiety disorders (cases 1 and 7).
Three patients (cases 2, 6, and 7) estimated that their ED developed before topiramate use. One additional adolescent (case 1) had a history of an ED in remission that recurred after topiramate initiation. The remaining 
DISCUSSION
To our knowledge, this case series is the first describing the development or exacerbation of ED symptoms after topiramate initiation in adolescents with migraine or chronic headache. Migraine and headaches are particularly common conditions seen in individuals with EDs, with one small study finding that at least 74% of patients with EDs also reported migraine. [19] [20] [21] The migraine and ED patient populations share characteristics including frequent symptom onset during adolescence, higher prevalence of female sufferers, common psychiatric comorbidities including depression and anxiety, and personality traits including perfectionism and feelings of ineffectiveness. 19, 21, 22 Consequently, several researchers have postulated a pathophysiological overlap in migraine and EDs, such as postsynaptic serotonin dysfunction or catecholamine abnormalities. 23 Of note, patients with POTS have also been found to share many of these clinical characteristics, 24 which might account for the high rate of comorbid POTS in this sample.
Although the methodology of this study is insufficient to clarify the direction of causality, these cases suggest that physicians should be aware of the overlap between migraine and EDs. In particular, it appears that patients who have ED symptoms or who are at risk for an ED should be observed closely after topiramate initiation because the medication might trigger or intensify ED symptoms. In the cases presented, it should be noted that at least 3 individuals (cases 2, 6, and 7) had a distinguishable ED before topiramate use. One additional patient (case 1) had a premorbid history of ED that had resolved by the time topiramate was introduced and relapsed after medication use.
These findings are consistent with previous case studies in which both adult cases had an ED history and relapsed after topiramate initiation. 16, 17 Although an understanding of the prevalence of cases in which EDs either develop or worsen in the context of topiramate prescription is beyond the scope of this article, it is clear that providers should consider the potential that the medication may exacerbate existing EDs and to screen carefully for ED symptoms before prescribing topiramate (Table 2) .
It should be noted that, although these 4 cases described clear preexisting ED pathology, none of these patients had received an ED diagnosis or treatment before initiating topiramate. This is in contrast to reported adult cases 16, 17 and is understandable given that the present cases are younger. Perhaps, over time, these patients' ED symptoms would have increased to the point of detection/diagnosis regardless of topiramate use. Nonetheless, because of the potential comorbidity between migraine and EDs, [19] [20] [21] 23 it is especially important for providers to remain aware of the possibility of undetected EDs in migraine patients.
In 3 cases, patients endorsed no ED symptoms before topiramate initiation, although 1 patient (case 3) reported a family history of ED. It is possible that all 3 cases had risk factors and/or subthreshold symptoms of EDs despite not exhibiting clinical levels of symptomatology. Unfortunately, disordered eating and related maladaptive cognitions are not uncommon in adolescents. 25 As such, clinicians must remain attentive to the potential development of EDs even in patients with no history of eating issues.
It is also theoretically possible for topiramate-induced weight loss to trigger an ED in a patient with no These 7 cases illustrate a need for practitioners prescribing topiramate to be aware of the potential for the medication to either trigger or worsen ED symptoms in young patients. This is particularly important given that topiramate has recently become the first medication approved for use in migraine prevention in adolescents. 1 Providers should carefully screen patients for preexisting EDs and/or ED risk factors before prescribing topiramate (Table 2) . Furthermore, careful monitoring of patient weight and eating behaviors should continue after topiramate initiation; weight loss/anorexia should be carefully monitored and not dismissed simply as a side effect of the medication.
